Suppr超能文献

美国1965 - 1992年哮喘治疗趋势

Trends in asthma therapy in the United States: 1965-1992.

作者信息

Terr A I, Bloch D A

机构信息

Stanford University Medical Center, Division of Immunology, California 94305, USA.

出版信息

Ann Allergy Asthma Immunol. 1996 Mar;76(3):273-81. doi: 10.1016/S1081-1206(10)63441-2.

Abstract

BACKGROUND

Many recent studies indicate an increasing morbidity and mortality of asthma in the past two decades. This study uses data from the National Disease and Therapeutic Index (NDTI) to document and analyze trends in drug therapy for asthma in the United States from 1965 through 1992.

METHODS

The NDTI maintains a continuous rotating national sampling of approximately 1% of US physicians in office-based practice proportionately representative of practicing generalists and specialists who report issuance of drugs in treatment by diagnosis for all patient encounters for a period of two days every 3 months. Annual summaries of five demographic categories and 14 drug categories, characterizing the asthma patient-physician encounters as percent of visits for the 28-year period of 1965 through 1992 are analyzed and characterized.

RESULTS

Physician visits for asthma treatment have shifted somewhat from generalists to specialists in internal medicine and pediatrics. Allergists treat a significant proportion of the asthmatic population. Most patients are seen in the office. There has been no significant change in rates of inpatient visits. Age distribution of the population of patient visits for asthma has been stable, but there is a steady drop in ratio of males to females. Since the mid-1970s, inhaled adrenergic bronchodilator prescriptions have been issued at a markedly increasing rate. Concurrently, issuance of xanthines and oral adrenergic drugs also rose dramatically but then decreased beginning in the mid-1980s. Corticosteroids are used in 15% to 20% of visits, but only recently has the inhaled route of administration shown prominence. Allergen immunotherapy for asthma has decreased more than 10-fold. Cromolyn is prescribed infrequently.

CONCLUSIONS

Major changes have occurred in drug treatment by physicians for asthma in the US since 1965. Bronchodilating drugs predominate, and they are being prescribed in more effective forms at a generally increasing rate. Corticosteroid use has increased at a slower rate and in smaller proportion of patient-visits, while allergen immunotherapy has dramatically declined. The male-to-female ratio of asthmatic patients who visit doctors for treatment appears to be decreasing.

摘要

背景

许多近期研究表明,在过去二十年中哮喘的发病率和死亡率呈上升趋势。本研究使用来自国家疾病与治疗指数(NDTI)的数据,记录并分析了1965年至1992年美国哮喘药物治疗的趋势。

方法

NDTI对约1%的美国门诊医生进行持续轮换抽样,这些医生具有代表性,涵盖全科医生和专科医生,他们每3个月报告连续两天所有患者就诊时按诊断分类的药物开具情况。分析并描述了1965年至1992年这28年间,五个人口统计学类别和14个药物类别年度总结中哮喘患者与医生就诊情况占总就诊次数的百分比。

结果

哮喘治疗的医生就诊情况已从全科医生有所转向内科和儿科专科医生。过敏症专科医生治疗了相当比例的哮喘患者群体。大多数患者在门诊就诊。住院就诊率没有显著变化。哮喘患者就诊人群的年龄分布一直稳定,但男性与女性的比例在稳步下降。自20世纪70年代中期以来,吸入性肾上腺素能支气管扩张剂的处方开具率显著上升。同时,黄嘌呤类药物和口服肾上腺素能药物的开具量也大幅上升,但在20世纪80年代中期开始下降。15%至20%的就诊患者使用皮质类固醇,但直到最近吸入给药途径才开始受到重视。哮喘的变应原免疫疗法减少了10倍以上。色甘酸钠的处方开具很少。

结论

自1965年以来,美国医生对哮喘的药物治疗发生了重大变化。支气管扩张药物占主导地位,且以更有效的形式开具,总体开具率不断上升。皮质类固醇的使用增长较慢,在患者就诊中所占比例较小,而变应原免疫疗法则大幅下降。因治疗而看医生的哮喘患者中,男性与女性的比例似乎在下降。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验